Atjaunināt sīkdatņu piekrišanu

Clinical Handbook of Psychotropic Drugs 20th edition [Spiral bound]

3.80/5 (10 ratings by Goodreads)
  • Formāts: Spiral bound, 382 pages, height x width x depth: 280x216x20 mm, weight: 1288 g, colour illustrations, colour tables
  • Izdošanas datums: 04-Sep-2013
  • Izdevniecība: Hogrefe Publishing
  • ISBN-10: 0889374511
  • ISBN-13: 9780889374515
Citas grāmatas par šo tēmu:
  • Spiral bound
  • Cena: 79,86 €*
  • * Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena
  • Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena.
  • Daudzums:
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Formāts: Spiral bound, 382 pages, height x width x depth: 280x216x20 mm, weight: 1288 g, colour illustrations, colour tables
  • Izdošanas datums: 04-Sep-2013
  • Izdevniecība: Hogrefe Publishing
  • ISBN-10: 0889374511
  • ISBN-13: 9780889374515
Citas grāmatas par šo tēmu:
Fully updated and expanded, in full color with intuitive icons throughout, packed with new and expanded comparison charts, and with patient handouts as printable PDFs - the classic reference to psychotropic medications is now more "userfriendly" than ever! The Clinical Handbook of Psychotropic Drugs has become a standard reference and practical tool for psychiatrists, psychiatric nurses, pharmacists, psychologists, physicians, and all mental health professionals.The new and fully updated 19th edition retains all the practical features for which the Clinical Handbook is renowned: Independent, unbiased Packed with unique comparison charts (dosages, side effects, pharmacokinetics, interactions - ) that allow you to see at a glance which medication is the most suitable for each patient Instantly recognizable icons and full color throughout, allowing you to find at a glance all the information you seek The latest information on newly released drugs, adverse effects, approved indications (see below for details) Succinct, bulleted information on all classes of medication: classification, available products (including US and Canadian trade names), on- and off-label indications (US FDA and Canada); pharmacology, dosing, pharmacokinetics; adverse effects, precautions, contraindications, toxicity; lab tests, precautions in young, old, and pregnant patients, nursing implications; drug interactions; patient instructions - all you need to know for each class of drug! The latest information on Herbal and "Natural" Products, Unapproved Treatments, ECT, BLT, rTMS Patient handouts as printable PDFs New in this edition: Substantial updates on antipsychotic dosages (2nd generation); Pharmacogenomics information for dementia drugs; Recent drugs / preparations added, such as Forfivo (bupropion), Levate (amitriptyline), Impril (imipramine pamoate), Mazepine (carbamazepine), Stavzor (valproate), Gralise (gabapentin), Horizant (gabapentin enacarbil), Trokendi XR (topiramate); Revised classification of antidepressants: vilazodone (Viibryd) as Serotonin-1A Agonist/Serotonin Reuptake Inhibitor

Recenzijas

"The best handbook pf psychotropics I've ever read. Practical, succinct, and better than anything else available." The comparison charts are easy to use and unique to this handbook and help me select the right medication for the patient." Carl Anderson, MD, Private Practice, Bronx, NY "[ A] user-friendly and practical resource guide for using psychotropic drugs in any setting. ... As a psychiatrist who routinely prescribes medications, I find this handbook invaluable. ... It is the most comprehensive book on this topic that I have come across." Corey Goldstein, MD (Rush University Medical Center) in Doody's Listings and Reviews, Dec. 2013

Antidepressants
2(73)
Selective Serotonin Reuptake Inhibitors (SSRI)
3(12)
Norepinephrine Dopamine Reuptake Inhibitor (NDRI)
15(6)
Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
21(6)
Serotonin-2 Antagonists/Reuptake Inhibitors (SARI)
27(6)
Serotonin-1A Agonist/Serotonin Reuptake Inhibitor
33(2)
Noradrenergic/Specific Serotonergic Antidepressants (NaSSA)
35(4)
Nonselective Cyclic Antidepressants
39(8)
Monoamine Oxidase Inhibitors
47(1)
Reversible Inhibitor of MAO-A (RIMA)
47(3)
Irreversible Monoamine Oxidase (A&B) Inhibitors (MAOIs)
50(6)
Irreversible MAO-B Inhibitor
56(4)
Effects of Antidepressants on Neurotransmit-ters/Receptors
60(1)
Pharmacological Effects of Antidepressants on Neurotransmitters/Receptors
61(1)
Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses
62(3)
Antidepressant Doses and Pharmacokinetics
65(3)
Switching Antidepressants
68(2)
Antidepressant Augmentation Strategies
70(5)
Electroconvulsive Therapy (ECT)
75(6)
Bright Light Therapy (BLT)
81(3)
Repetitive Transcranial Magnetic Stimulation (rTMS)
84(4)
Antipsychotics
88(94)
"Second-Generation" Antipsychotics/SGAs
96(31)
"Third-Generation" Antipsychotic/TGA
127(10)
"First-Generation" Antipsychotics/FGAs
137(19)
Effects of Antipsychotics on Neurotransmitters/Receptors
156(1)
Pharmacological Effects of Antipsychotics on Neurotransmitters/Receptors
157(1)
Frequency (%) of Adverse Reactions to Antipsychotics at Therapeutic Doses
158(2)
Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections)
160(10)
Comparison of Long-Acting IM Antipsychotics
170(4)
Switching Antipsychotics
174(1)
Antipsychotic Augmentation Strategies
175(7)
Antipsychotic-Induced Extrapyramidal Side Effects and Their Management
182(14)
Extrapyramidal Adverse Effects of Antipsychotics
182(4)
Treatment Options for Extrapyramidal Side Effects
186(4)
Effects on Extrapyramidal Symptoms
190(1)
Comparison of Agents for Treating Acute Extrapyramidal Side Effects
191(2)
Doses and Pharmacokinetics of Agents for Treating Acute Extrapyramidal Side Effects
193(3)
Anxiolytic (Antianxiety) Agents
196(17)
Benzodiazepines
196(8)
Comparison of the Benzodiazepines
204(5)
Buspirone
209(4)
Hypnotic/Sedatives
213(14)
L-Tryptophan
218(3)
Comparison of Hypnotics/Sedatives
221(6)
Mood Stabilizers
227(33)
Lithium
227(8)
Anticonvulsants
235(14)
Comparison of Anticonvulsants
249(8)
Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic Doses
257(3)
Drugs for ADHD
260(20)
Psychostimulants
260(8)
Atomoxetine
268(3)
Comparison of Drugs for ADHD
271(4)
α2 agonists
275(3)
Augmentation Strategies in ADHD
278(2)
Drugs for Treatment of Dementia
280(12)
Cholinesterase Inhibitors
280(5)
Memantine
285(2)
Comparison of Drugs for Treatment of Dementia
287(5)
Sex-Drive Depressants
292(4)
Comparison of sex-Drive Depressants
294(2)
Drugs of Abuse
296(30)
Alcohol
298(5)
Stimulants
303(5)
Hallucinogens
308(7)
Opioids/Narcotics
315(3)
Inhalants/Aerosols
318(2)
Gamma-hydroxybutyrate (GHB)/Sodium Oxybate
320(2)
Flunitrazepam (Rohypnol)
322(1)
Nicotine/Tobacco
323(3)
Treatment of Substance Use Disorders
326(21)
Disulfiram
326(3)
Acamprosate
329(2)
Naltrexone
331(3)
Methadone
334(4)
Buprenorphine
338(3)
Pharmacotherapy for Nicotine/Tobacco Use Dependence
341(6)
Unapproved Treatments of Psychiatric Disorders
347(12)
Adrenergic Agents
348(2)
Dopaminergic Agents
350(2)
GABA Agents/Anticonvulsants
352(2)
Hormones
354(2)
NMDA Agents
356(1)
Miscellaneous
357(2)
Natural Health Products
359(9)
Glossary 368(4)
Suggested Resources for Information Regarding Drug Use in Pregnancy and Effects on Breast Milk 372(1)
Patient Information Sheets 373(1)
Index of Drugs 374